Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:138-142

Characteristics of cancer-associated adverse event reports

Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:138-142

(A) Rates of cancer adverse event reports in patients treated with

the combination ezetimibe/simvastatin

and other potent cholesterol-lowering

drugs (B) The proportion of cancer adverse event reports relative to all

reported adverse events in patients treated with the

combination ezetimibe/simvastatin

and other potent cholesterol lowering

drugs

*P<.01 versus ezetimibe/simvastatin.

†P<.01 versus ezetimibe

Alsheikh-Ali AA, Karas RH. J Clin Lip 2009;3:138-142

Rates of cancer associated adverse event reports in patients treated with the combination ezetimibe/simvastatin

(E/S) and other potent cholesterol lowering drugs (rate per million prescriptions)

Alsheikh-Ali AA, Karas RH. Journal of Clinical Lipidology 2009;3:138-142